Hydrophobic Interaction Chromatography Flow-Through Antibody Purification

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

There is a need for high-efficiency methods to purify antibody products from process-related impurities and product-related substances at a low cost, as these impurities can impact product stability, safety, and efficacy in commercially produced recombinant bio-therapeutics.

Innovation Solution

The method involves using hydrophobic interaction chromatography (HIC) media to bind both the protein of interest and non-product proteins, followed by a wash with a similar aqueous salt solution to collect unbound protein reduced in impurities, and then recovering the bound product, while the impurities remain bound to the HIC media.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional HIC is used to retain antibody product on chromatographic support, then product can be separated from impurities, but process cost increases and purification efficiency decreases

Engineering Contradiction:
Improvepurification efficiencyVSAvoidprocess cost
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent inverts the conventional HIC approach by using a hydrophobic ligand-containing resin in flow-through mode where impurities bind to the hydrophobic ligands while the antibody product flows through unbound. This reversal of the binding/elution strategy eliminates the need for complex gradient elution protocols and reduces process steps while maintaining high purification efficiency

Inventive Principle:
Principle #13The other way round (Inversion)

Solution Approach 2:

The patent extracts and removes the complex elution step from the conventional HIC process. By using a simple wash buffer composition that matches the load buffer, the method eliminates the need for separate elution steps involving gradient formation, thereby simplifying the overall process and reducing operational complexity

Inventive Principle:
Principle #2Taking out (Extraction)

2Productivity

If conventional HIC elution methods are used, then antibody product can be recovered, but additional elution steps increase process complexity and time

Engineering Contradiction:
Improvepurification speedVSAvoidprocess time
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by designing the load buffer composition to be identical to or very similar to the wash buffer composition. This preliminary matching of buffer conditions ensures that the antibody product remains unbound during loading and can be directly collected in the flow-through fraction, eliminating the need for subsequent elution steps and significantly reducing process time

Inventive Principle:
Principle #10Preliminary action

3Manufacturing precision

If multiple chromatography steps are used to reduce impurities, then product purity increases, but process complexity and cost increase

Engineering Contradiction:
Improveproduct purityVSAvoidprocess simplicity
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent applies universality by using a single hydrophobic interaction chromatography step that simultaneously achieves multiple purification objectives: removal of host cell proteins, removal of aggregates, and concentration of the antibody product. This multi-functional approach consolidates what would traditionally require multiple separate chromatography steps into one operation, thereby simplifying the manufacturing process while maintaining high product purity

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent merges the functions of impurity removal and product concentration into a single flow-through chromatography step. By combining these functions that would traditionally require separate steps into one operation using a hydrophobic ligand-containing resin, the method reduces the total number of process steps and simplifies manufacturing while achieving the desired product purity

Inventive Principle:
Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively reduces process-related impurities and product-related substances, enhancing the purity and stability of antibody products, thereby improving product safety and efficacy.

Implementation Method 1

Hydrophobic interaction chromatography (HIC) media interact with hydrophobic regions present on an antibody of interest

Methodology Applied
Scientific EffectHydrophobic interaction: Hydrophobe

Implementation Method 2

contacting a sample mixture comprising the protein of interest with a hydrophobic chromatographic media in an aqueous salt solution under loading conditions that permit both the product and non-product proteins to bind to the hydrophobic media

Methodology Applied
Scientific EffectChromatography: Chromatography

Implementation Method 3

collecting the unbound product that is substantially reduced in process-related impurities and/or product-related substances from the media

Methodology Applied
Scientific EffectAdsorption: Adsorption

Data Source

PatentUS9249182B2Purification of antibodies using hydrophobic interaction chromatography
Publication Date: 2016.02.02 ABBVIE INC
  • US9249182B2 patent drawing
  • US9249182B2 patent drawing
  • US9249182B2 patent drawing

AI summary

Disclosed herein are compositions and methods for purifying antibody products from a sample matrix. In particular, the present invention relates to compositions and methods for purifying antibody products employing hydrophobic interaction chromatography media. In certain embodiments, the invention provides a method for reducing process-related impurities (e.g., host cell proteins), as well as product-related substances, including molecular weight variants (e.g., aggregates and fragments of the antibody product).